M6620: Clinical Trials

13 trials of M6620, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 active not recruiting, 6 completed. 13 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Active not recruiting 7, Completed 6
Phase 23Active not recruiting 2, Completed 1

Follow M6620: new trials by email Literature Review of M6620 trials Research Report on M6620

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
[14C]Berzosertib, Berzosertib, Topotecan - Advanced Solid Tumor
Phase 1CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany62022-02-152024-11-22
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)122021-04-142026-11-18
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment - Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)422020-09-242026-11-18
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center232020-03-172026-11-10
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
M6620, Avelumab, Carboplatin - Ovarian Cancer
Phase 1CompletedEMD Serono Research & Development Institute, Inc.32019-03-042020-11-13
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
M6620, Cisplatin, Capecitabine - Oesophageal Adenocarcinoma, Squamous Cell Carcinoma
Phase 1CompletedUniversity of Oxford362018-12-042024-07-18
ATRi Transition Rollover Study
Berzosertib - Advanced Stage Solid Tumors
Phase 1CompletedMerck KGaA, Darmstadt, Germany12018-01-102024-11-29
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery - Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)152017-05-222026-11-18
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Berzosertib, Carboplatin, Gemcitabine Hydrochloride - Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)352017-05-162026-11-18
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
Berzosertib, Cisplatin, Computed Tomography - Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)432017-04-172026-11-18
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)662016-07-222026-11-18
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Topotecan, VX-970 (M6620) - Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)622015-07-302025-04-13
M6620 First in Human Study
M6620, Gemcitabine, Cisplatin - Advanced Solid Tumor
Phase 1CompletedEMD Serono Research & Development Institute, Inc.2002012-12-102020-04-01

Conditions studied

Lung Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Small Cell Lung Carcinoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Fallopian Tube Neoplasms (2)  ·  Hereditary Sensory and Autonomic Neuropathies (2)  ·  Neoplasm Metastasis (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Squamous Cell (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  EMD Serono Research & Development Institute, Inc. (2)  ·  M.D. Anderson Cancer Center (1)  ·  Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  University of Oxford (1)

Countries

United States (10)  ·  United Kingdom (4)  ·  Belgium (1)  ·  Hungary (1)

Top investigators

Liza C Villaruz (2)  ·  Andrea E Wahner Hendrickson (1)  ·  Anish Thomas, M.D. (1)  ·  Maria A Hawkins, MD FRCR MRCP (1)  ·  Pranshu Mohindra (1)  ·  Robert W Mutter (1)  ·  Taofeek K Owonikoko (1)  ·  Timothy A Yap (1)

Results publications

PMID 29252124, PMID 32571298, PMID 33145616, PMID 34040174, PMID 34040175, PMID 38129525, PMID 40437704, PMID 41206673, PMID 42820295

NIH funding

UM1CA186690 (4), UM1CA186686 (3), UM1CA186691 (2), UM1CA186709 (2), 2017 (1), 2018 (1), N01CM00099 (1), N01CM00100 (1), P30CA015083 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186704 (1), UM1CA186717 (1)